BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 10, 2003
 |  BioCentury  |  Emerging Company Profile

Genfit: Tracking nuclear receptors

Nuclear receptors are considered highly druggable targets, but their complex biology presents challenges to describing their role in disease. Genfit S.A. applies its expertise in nuclear receptors and ligand-dependent activation of gene transcription to understand the roles of nuclear receptors in disease and develop drugs to manipulate them.

"For many reasons, nuclear receptors are very druggable targets: the binding domains are well defined; they have been very well conserved during evolution; and they are involved in many diseases including atherosclerosis, diabetes and aging," said CEO Jean-François Mouney.

Nuclear receptors also are known to play a key role in gene transcription. "About 50 nuclear receptors have been identified, but their mechanisms of action as transcription factors are very complicated, and involve many co-regulators," Mouney said. "We believe that if you understand their mechanism of action, then you are in a good position to find drugs."


Read the full 718 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >